Bellerophon Provides Update on INOpulse Phase 2b Clinical Program for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
Bellerophon Announces Results of Interim Analysis of Phase 3 INOvation-1 Study Evaluating INOpulse for Treatment of Pulmonary Arterial Hypertension
Brunswick Exploration Announces Brokered Private Placement for Gross Proceeds of up to C$2.5 Million, with a Lead Order from a Strategic Investor
RETRANSMISSION: Group Eleven to be Featured on Radius Research for a Live Company Pitch, Deep Dive and Q&A Webinar
